We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Lockheed Martin
LMT
$134B
| $13.3M | 0.03% |
82,521
-18,165
| -18% | -$2.95M |
|
|
SDRL
302
DELISTED
Seadrill Limited Common Stock
SDRL
| $13.1M | 0.03% |
1,225
+174
| +17% | +$1.7M |
|
303
MasTec
MTZ
$24.7B
| $13.1M | 0.03% |
424,758
+236,968
| +126% | +$8.93M |
|
|
304
Gilead Sciences
GILD
$167B
| $12.8M | 0.03% |
154,286
-3,369,687
| -96% | -$262M |
|
305
Constellation Brands
STZ
$22.5B
| $12.7M | 0.03% |
144,165
| – | – |
|
|
NSR
306
DELISTED
Neustar Inc
NSR
| $12.7M | 0.03% |
487,367
+295,853
| +154% | +$8.04M |
|
307
Wintrust Financial
WTFC
$10.9B
| $12.6M | 0.03% |
274,459
+40,162
| +17% | +$1.82M |
|
308
Woodward
WWD
$24.5B
| $12.6M | 0.03% |
250,681
+21,094
| +9% | +$961K |
|
309
State Street SPDR Nuveen ICE Short Term Municipal Bond ETF
SHM
$3.46B
| – | – |
0
| – | – |
|
|
SGF
310
DELISTED
Aberdeen Singapore Fund
SGF
| $12.4M | 0.03% |
949,572
-40,356
| -4% | -$523K |
|
311
Koppers
KOP
$965M
| $12.3M | 0.03% |
+322,776
| New | +$12.6M |
|
312
iShares S&P 100 ETF
OEF
$19.8B
| $12.3M | 0.03% |
+142,045
| New | +$12M |
|
313
Biogen
BIIB
$30.4B
| $12.2M | 0.03% |
38,790
+26,673
| +220% | +$8.03M |
|
314
Arch Capital
ACGL
$37.2B
| $12.2M | 0.03% |
634,707
+46,005
| +8% | +$876K |
|
|
BCF
315
DELISTED
BLACKROCK REAL ASSET EQUITY TRUST
BCF
| $12.1M | 0.03% |
1,293,125
+1,006,087
| +351% | +$9.23M |
|
|
FITB
316
Fifth Third Bancorp
FITB
$52.4B
| $12M | 0.03% |
563,225
-90,111
| -14% | -$1.91M |
|
317
iShares Expanded Tech Sector ETF
IGM
$9.78B
| $12M | 0.03% |
757,650
+693,390
| +1,079% | +$10.6M |
|
318
Brookdale Senior Living
BKD
$3.67B
| $12M | 0.03% |
360,442
+4,740
| +1% | +$154K |
|
319
Aflac
AFL
$65.9B
| $11.9M | 0.02% |
382,256
+89,472
| +31% | +$2.79M |
|
320
iShares Global Industrials ETF
EXI
$1.41B
| $11.8M | 0.02% |
161,990
-38,310
| -19% | -$2.77M |
|
321
BlackRock Resources & Commodities Strategy Trust
BCX
$891M
| $11.7M | 0.02% |
945,450
+772,183
| +446% | +$9.33M |
|
322
Simon Property Group
SPG
$76.8B
| $11.7M | 0.02% |
70,512
+1,443
| +2% | +$236K |
|
|
TTF
323
DELISTED
Thai Fund
TTF
| $11.6M | 0.02% |
1,031,845
-5,925
| -0.6% | -$67.6K |
|
324
iShares MSCI France ETF
EWQ
$329M
| $11.5M | 0.02% |
393,185
+208,615
| +113% | +$6.22M |
|
|
VER
325
DELISTED
VEREIT, Inc.
VER
| $11.3M | 0.02% |
180,438
+145,599
| +418% | +$9.36M |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.